Onvansertib + Paclitaxel In TNBC

Inclusion Criteria: * Histologically confirmed invasive breast cancer with unresectable locally advanced or metastatic disease, included inflammatory breast cancer * Histologically or cytologically-confirmed triple negative breast cancer (defined as ER ≤ 10%, PR ≤ 10%, Her-2-neu negative per ASCO/CAP 2018 guidelines: 0-1+ by IHC or FISH-negative) * Concurrent endocrine therapy will not be allowed for patients with ER/PR ≥1% * Age ≥ 18 years * ECOG Performance Status of 0 or 1. * Subjects must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines * Subject is not receiving any other cancer therapy. Subjects participating in surveys or observational studies are allowed. * Subjects with treated brain metastases that are stable on imaging for at least four weeks prior to registration and who are off steroid therapy are eligible. Subjects with small, asymptomatic incidental brain metastases that require no immediate treatment, including steroids, are also eligible. * For a male or a woman of child-bearing potential (WOCBP): Must agree to use contraception or take measures to avoid pregnancy during the study and for 180 days of the final dose of any study drug. * Adequate contraception is defined as follows: * Complete true abstinence. * Consistent and correct use of one of the following methods of birth control: * Male partner who is sterile prior to the female …